Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato(Translational Research in Oncology), Yasuhiro Funahashi(Eisai (United States))
Cited by 458
Related Papers
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
|Journal of Thyroid Research|2014|479
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
|Cancer Science|2017|65
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
|Scientific Reports|2020|59